Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Galena Biopharma Inc (NASDAQ:GALE)

1.63
Delayed Data
As of Aug 03
 -0.01 / -0.61%
Today’s Change
1.27
Today|||52-Week Range
3.16
+7.95%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$265.2M

Company Description

Galena Biopharma, Inc. is a biotechnology company focused on discovering, developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. Its development portfolio ranges from mid to late stage clinical assets which include program led by NeuVax. The company's commercial drugs include Abstral (fentanyl) Sublingual Tablets and Zuplenz (ondansetron) Oral Soluble Film. The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Galena Biopharma was founded by Craig Mello on April 3, 2006 and is headquartered in Portland, OR.

Contact Information

Galena Biopharma, Inc.
4640 SW Macadam Avenue
Portland Oregon 97239
P:(855) 855-4253
Investor Relations:
(503) 405-8258

Employees

Shareholders

Other institutional9.79%
Mutual fund holders10.22%
Individual stakeholders0.43%

Top Executives

Mark W. SchwartzPresident, Chief Executive Officer & Director
Gavin S. ChoySenior VP-Clinical Sciences & Operations
Ryan M. DunlapVP, Chief Financial & Accounting Officer
Patricia A. MurphyVice President-Regulatory & Compliance
Christopher S. LentoSenior Vice President-Commercial Operations